Early switch maintenance in gastric cancer: who benefits most?
First-line treatments have historically relied on fluoropyrimidine and platinum agents, but more recent approaches incorporate biomarker-guided targeted therapies, including those based on PD-L1 combined positive score, mismatch repair status or microsatellite instability, and claudin-18.2 expressio...
Gespeichert in:
Veröffentlicht in: | The lancet oncology 2024-12, Vol.25 (12), p.1508-1509 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1509 |
---|---|
container_issue | 12 |
container_start_page | 1508 |
container_title | The lancet oncology |
container_volume | 25 |
creator | Sakakida, Tomoki Kadowaki, Shigenori |
description | First-line treatments have historically relied on fluoropyrimidine and platinum agents, but more recent approaches incorporate biomarker-guided targeted therapies, including those based on PD-L1 combined positive score, mismatch repair status or microsatellite instability, and claudin-18.2 expression. Paclitaxel plus ramucirumab has gained recognition as an effective second-line therapy.6 Additionally, a systematic review of 25 phase 3 trials confirmed a strong association between the rate of subsequent chemotherapy and overall survival improvements in gastric cancer.7 Collectively, these findings underscore the critical importance of timely treatment transitions to optimise survival. In the control group, the overall response rate was 16% with ongoing chemotherapy, whereas 32% showed disease progression.1 The switch maintenance group showed an overall response rate (19%) that was similar to the control group but only 9% had progressive disease; disease control was achieved by 85% of individuals who received switch maintenance therapy. |
doi_str_mv | 10.1016/S1470-2045(24)00659-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3130207018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204524006594</els_id><sourcerecordid>3130207018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-8e5049d5d6e8ab3cca445c1d5538c9b050eb175717ae521a9dde5f045063f42c3</originalsourceid><addsrcrecordid>eNqFkE1PwzAMhiMEgjH4CaBKXMah4LRx03JgQhNfEhIH4BylqQtBawtJB9q_J1uBAxdOtqzH9quHsQMOJxx4dvrAhYQ4AYGTRBwDZFjEYoONwljEKPJ8c90PyA7b9f4VgEsOuM120gJRAsoRO7_Ubr6M_KftzUvUaNv21OrWUGTb6Fn73lkTmdXAnUWfL11UUku17X3UdL6f7rGtWs897X_XMXu6unyc3cR399e3s4u72CSS93FOCKKosMoo12VqjBYCDa8Q09wUJSBQySVKLjVhwnVRVYR1CA5ZWovEpGM2Ge6-ue59Qb5XjfWG5nPdUrfwKuUpJCCB5wE9-oO-dgvXhnQrCgF58BAoHCjjOu8d1erN2Ua7peKgVoLVWrBa2VOJUGvBSoS9w-_ri7Kh6nfrx2gApgNAQceHJae8sRT8VdaR6VXV2X9efAHv_4hU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3135051001</pqid></control><display><type>article</type><title>Early switch maintenance in gastric cancer: who benefits most?</title><source>Elsevier ScienceDirect Journals</source><creator>Sakakida, Tomoki ; Kadowaki, Shigenori</creator><creatorcontrib>Sakakida, Tomoki ; Kadowaki, Shigenori</creatorcontrib><description>First-line treatments have historically relied on fluoropyrimidine and platinum agents, but more recent approaches incorporate biomarker-guided targeted therapies, including those based on PD-L1 combined positive score, mismatch repair status or microsatellite instability, and claudin-18.2 expression. Paclitaxel plus ramucirumab has gained recognition as an effective second-line therapy.6 Additionally, a systematic review of 25 phase 3 trials confirmed a strong association between the rate of subsequent chemotherapy and overall survival improvements in gastric cancer.7 Collectively, these findings underscore the critical importance of timely treatment transitions to optimise survival. In the control group, the overall response rate was 16% with ongoing chemotherapy, whereas 32% showed disease progression.1 The switch maintenance group showed an overall response rate (19%) that was similar to the control group but only 9% had progressive disease; disease control was achieved by 85% of individuals who received switch maintenance therapy.</description><identifier>ISSN: 1470-2045</identifier><identifier>ISSN: 1474-5488</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(24)00659-4</identifier><identifier>PMID: 39557057</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biomarkers ; Cancer therapies ; Chemotherapy ; Disease control ; Gastric cancer ; Medical prognosis ; Microsatellite instability ; Mismatch repair ; Paclitaxel ; Patients ; PD-L1 protein ; Response rates ; Survival</subject><ispartof>The lancet oncology, 2024-12, Vol.25 (12), p.1508-1509</ispartof><rights>2024 Elsevier Ltd</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c271t-8e5049d5d6e8ab3cca445c1d5538c9b050eb175717ae521a9dde5f045063f42c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1470204524006594$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39557057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sakakida, Tomoki</creatorcontrib><creatorcontrib>Kadowaki, Shigenori</creatorcontrib><title>Early switch maintenance in gastric cancer: who benefits most?</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>First-line treatments have historically relied on fluoropyrimidine and platinum agents, but more recent approaches incorporate biomarker-guided targeted therapies, including those based on PD-L1 combined positive score, mismatch repair status or microsatellite instability, and claudin-18.2 expression. Paclitaxel plus ramucirumab has gained recognition as an effective second-line therapy.6 Additionally, a systematic review of 25 phase 3 trials confirmed a strong association between the rate of subsequent chemotherapy and overall survival improvements in gastric cancer.7 Collectively, these findings underscore the critical importance of timely treatment transitions to optimise survival. In the control group, the overall response rate was 16% with ongoing chemotherapy, whereas 32% showed disease progression.1 The switch maintenance group showed an overall response rate (19%) that was similar to the control group but only 9% had progressive disease; disease control was achieved by 85% of individuals who received switch maintenance therapy.</description><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Disease control</subject><subject>Gastric cancer</subject><subject>Medical prognosis</subject><subject>Microsatellite instability</subject><subject>Mismatch repair</subject><subject>Paclitaxel</subject><subject>Patients</subject><subject>PD-L1 protein</subject><subject>Response rates</subject><subject>Survival</subject><issn>1470-2045</issn><issn>1474-5488</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkE1PwzAMhiMEgjH4CaBKXMah4LRx03JgQhNfEhIH4BylqQtBawtJB9q_J1uBAxdOtqzH9quHsQMOJxx4dvrAhYQ4AYGTRBwDZFjEYoONwljEKPJ8c90PyA7b9f4VgEsOuM120gJRAsoRO7_Ubr6M_KftzUvUaNv21OrWUGTb6Fn73lkTmdXAnUWfL11UUku17X3UdL6f7rGtWs897X_XMXu6unyc3cR399e3s4u72CSS93FOCKKosMoo12VqjBYCDa8Q09wUJSBQySVKLjVhwnVRVYR1CA5ZWovEpGM2Ge6-ue59Qb5XjfWG5nPdUrfwKuUpJCCB5wE9-oO-dgvXhnQrCgF58BAoHCjjOu8d1erN2Ua7peKgVoLVWrBa2VOJUGvBSoS9w-_ri7Kh6nfrx2gApgNAQceHJae8sRT8VdaR6VXV2X9efAHv_4hU</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Sakakida, Tomoki</creator><creator>Kadowaki, Shigenori</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202412</creationdate><title>Early switch maintenance in gastric cancer: who benefits most?</title><author>Sakakida, Tomoki ; Kadowaki, Shigenori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-8e5049d5d6e8ab3cca445c1d5538c9b050eb175717ae521a9dde5f045063f42c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Disease control</topic><topic>Gastric cancer</topic><topic>Medical prognosis</topic><topic>Microsatellite instability</topic><topic>Mismatch repair</topic><topic>Paclitaxel</topic><topic>Patients</topic><topic>PD-L1 protein</topic><topic>Response rates</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sakakida, Tomoki</creatorcontrib><creatorcontrib>Kadowaki, Shigenori</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sakakida, Tomoki</au><au>Kadowaki, Shigenori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early switch maintenance in gastric cancer: who benefits most?</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2024-12</date><risdate>2024</risdate><volume>25</volume><issue>12</issue><spage>1508</spage><epage>1509</epage><pages>1508-1509</pages><issn>1470-2045</issn><issn>1474-5488</issn><eissn>1474-5488</eissn><abstract>First-line treatments have historically relied on fluoropyrimidine and platinum agents, but more recent approaches incorporate biomarker-guided targeted therapies, including those based on PD-L1 combined positive score, mismatch repair status or microsatellite instability, and claudin-18.2 expression. Paclitaxel plus ramucirumab has gained recognition as an effective second-line therapy.6 Additionally, a systematic review of 25 phase 3 trials confirmed a strong association between the rate of subsequent chemotherapy and overall survival improvements in gastric cancer.7 Collectively, these findings underscore the critical importance of timely treatment transitions to optimise survival. In the control group, the overall response rate was 16% with ongoing chemotherapy, whereas 32% showed disease progression.1 The switch maintenance group showed an overall response rate (19%) that was similar to the control group but only 9% had progressive disease; disease control was achieved by 85% of individuals who received switch maintenance therapy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>39557057</pmid><doi>10.1016/S1470-2045(24)00659-4</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1470-2045 |
ispartof | The lancet oncology, 2024-12, Vol.25 (12), p.1508-1509 |
issn | 1470-2045 1474-5488 1474-5488 |
language | eng |
recordid | cdi_proquest_miscellaneous_3130207018 |
source | Elsevier ScienceDirect Journals |
subjects | Biomarkers Cancer therapies Chemotherapy Disease control Gastric cancer Medical prognosis Microsatellite instability Mismatch repair Paclitaxel Patients PD-L1 protein Response rates Survival |
title | Early switch maintenance in gastric cancer: who benefits most? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A24%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20switch%20maintenance%20in%20gastric%20cancer:%20who%20benefits%20most?&rft.jtitle=The%20lancet%20oncology&rft.au=Sakakida,%20Tomoki&rft.date=2024-12&rft.volume=25&rft.issue=12&rft.spage=1508&rft.epage=1509&rft.pages=1508-1509&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(24)00659-4&rft_dat=%3Cproquest_cross%3E3130207018%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3135051001&rft_id=info:pmid/39557057&rft_els_id=S1470204524006594&rfr_iscdi=true |